Allen A. Fienberg
Corporate Officer/Principal at ITI, Inc. (New York)
Profile
Allen A.
Fienberg was the founder of Intra-Cellular Therapies, Inc. (founded in 2002) where he held the title of Vice President-Business Development from 2011 to 2013.
He currently holds the title of Vice President-Business Development at ITI, Inc. ( New York).
Dr. Fienberg was a Research Assistant Professor at The Rockefeller University from 2001 to 2002.
He was also a Staff Scientist at Novartis Institute for Functional Genomics, Inc. in 2013.
In addition, he held the title of Vice President-Business Development at Intra-Cellular Therapies, Inc. Dr. Fienberg received a doctorate degree from Yale University in 1991 and an undergraduate degree from the University of California, Berkeley.
Allen A. Fienberg active positions
Companies | Position | Start |
---|---|---|
ITI, Inc. (New York) | Corporate Officer/Principal | - |
Former positions of Allen A. Fienberg
Companies | Position | End |
---|---|---|
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY. | Founder | 25/09/2013 |
The Rockefeller University | Corporate Officer/Principal | 31/12/2001 |
INTRA-CELLULAR THERAPIES, INC. | Corporate Officer/Principal | - |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Training of Allen A. Fienberg
Yale University | Doctorate Degree |
University of California, Berkeley | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
INTRA-CELLULAR THERAPIES, INC. | Health Technology |
Private companies | 3 |
---|---|
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY. | Health Technology |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
ITI, Inc. (New York) |
- Stock Market
- Insiders
- Allen A. Fienberg